Last reviewed · How we verify
Chemotherapy-Induced Hypogonadism — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Androgel | TESTOSTERONE | Besins Hlthcare | Androgen [EPC] | Androgen receptor | 1972-01-01 | |
| Testosteron | Testosteron | Gulhane School of Medicine | Corticosteroid-binding globulin, Alpha-synuclein, Lanosterol 14-alpha demethylase |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Besins Hlthcare · 1 drug in Chemotherapy-Induced Hypogonadism
- Gulhane School of Medicine · 1 drug in Chemotherapy-Induced Hypogonadism
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Chemotherapy-Induced Hypogonadism:
- Chemotherapy-Induced Hypogonadism treatment updates — RSS
- Chemotherapy-Induced Hypogonadism treatment updates — Atom
- Chemotherapy-Induced Hypogonadism treatment updates — JSON
Cite this brief
Drug Landscape (2026). Chemotherapy-Induced Hypogonadism — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/chemotherapy-induced-hypogonadism. Accessed 2026-06-10.
Related
- Chemotherapy-Induced Hypogonadism full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing